GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis
W. L. Gore & Associates, Inc. · Decision date Jul 1, 2026
What did the FDA approve?
FDA records P230023/S012 as a supplement to PMA P230023, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Jul 1, 2026.
FDA approval order statement
Approval of updates to the IFU (new warning statements)
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Cardiovascular
- Decision date
- Jul 1, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P230023/S012
- Regulatory pathway
- PMA supplement
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- QZK
- Decision code
- APPR
- Decision date
- Jul 1, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Endovascular system for treatment of thoracoabdominal and pararenal aortic lesions.
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- QZK
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P230023/S009 · Related supplement
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis
P230023/S010 · Related supplement
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis
P230023/S011 · Related supplement
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE)
P230023/S012 received
Application receipt date recorded by FDA.
P230023/S012 · FDA decision
Special (Immediate Track)
Timeline entries are records held by MedtechLedger for P230023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | PMA supplement | Sep 9, 2025 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Jan 15, 2026 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Apr 9, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
W. L. Gore & Associates, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3450 W. Kiltie Ln., Flagstaff, AZ, 86005
Sources and methodology
- Original FDA record: P230023/S012
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

